🔎 Trials Near Me

መነሻ › የሳንባ በሽታዎች › ማሳቹሴትስ › Boston

በBoston፣ MA ለየሳንባ በሽታዎች የሚደረጉ ክሊኒካዊ ጥናቶች

ለየሳንባ በሽታዎች የሚደረጉ 14 ጥናቶች በBoston እና በአካባቢው ባሉ ቦታዎች (በወደ 30 ማይል ውስጥ) ተሳታፊዎችን እየፈለጉ ነው። ማን መሳተፍ እንደሚችል እና የጥናት ቡድኑን እንዴት መገናኘት እንደሚቻል ለማየት ጥናቱን ክፈቱ።

Official study text (English)

ለጥናት ተሳታፊዎችን እየፈለጉ ነው? በዚህ ገጽ ላይ በ$99 ለ30 ቀናት ያስቀምጡት →

Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

ተሳታዮችን በመፈለግ ላይደረጃ 3
  • Dana-Farber Cancer Institute, Boston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ30 ሴፕቴ 2026 · NCT06765109

A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease

ተሳታዮችን በመፈለግ ላይደረጃ 3
  • Brigham and Women's Hospital, Boston
እድሜ 12 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ25 ሴፕቴ 2026 · NCT06679140

A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised

ተሳታዮችን በመፈለግ ላይደረጃ 3
  • Brigham and Women's Hospital, Boston
  • Clinical Trials Center, Boston
  • Clinical Trials Hub, Boston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ25 ሴፕቴ 2026 · NCT07013474

A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)

ተሳታዮችን በመፈለግ ላይደረጃ 2
  • Brigham and Women's Hospital, Boston
እድሜ ከ40 እስከ 75 · ሁሉም ጾታዎች · የተሻሻለው በ25 ሴፕቴ 2026 · NCT07759245

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

ተሳታዮችን በመፈለግ ላይደረጃ 1/2
  • Dana Farber Cancer Institute, Boston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ22 ሴፕቴ 2026 · NCT06128551

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

ተሳታዮችን በመፈለግ ላይደረጃ 3
  • Boston Medical Center, Boston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ8 ሴፕቴ 2026 · NCT06119581

A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD

ተሳታዮችን በመፈለግ ላይደረጃ 2
  • Clinical Research Site, Boston
እድሜ ከ18 እስከ 85 · ሁሉም ጾታዎች · የተሻሻለው በ2 ሴፕቴ 2026 · NCT07333183

A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.

ተሳታዮችን በመፈለግ ላይደረጃ 2
  • Beth Israel Deaconess Medical Center, Boston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ1 ሴፕቴ 2026 · NCT05967689

A Phase II Study to Investigate Lung Function With 2 Different Doses of Inhaled Glycopyrronium Taken With BFF Compared to BFF in Participants of 4 to Less Than 12 Years of Age With Asthma

ተሳታዮችን በመፈለግ ላይደረጃ 2
  • Research Site, Boston
እድሜ ከ4 እስከ 11 · ሁሉም ጾታዎች · የተሻሻለው በ27 ኦገስ 2026 · NCT07525375

BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)

ተሳታዮችን በመፈለግ ላይደረጃ 2
  • Dana-Farber Cancer Institute, Boston
  • Boston Children's Hospital, Boston
  • Brigham and Women's Hospital, Boston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ10 ጁን 2026 · NCT05922761

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

ተሳታዮችን በመፈለግ ላይደረጃ 1/2
  • Massachusetts General Hospital,, Boston
እድሜ 12 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ27 ሜይ 2026 · NCT03093116

Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy

ተሳታዮችን በመፈለግ ላይ
  • VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA, Boston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ19 ፌብሩ 2026 · NCT02984761

A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)

ተሳታዮችን በመፈለግ ላይደረጃ 2
  • Dana-Farber Cancer Institute, Boston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ15 ዲሴም 2025 · NCT06619561

Treatment of Pulmonary Arterial Hypertension Using the Aria CV Pulmonary Hypertension System

ተሳታዮችን በመፈለግ ላይ
  • Brigham and Women's Hospital, Boston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ29 ሴፕቴ 2025 · NCT04555161

በሌሎች ከተሞች ለየሳንባ በሽታዎች የሚደረጉ ጥናቶች

በBoston ውስጥ ያሉ ሌሎች ጥናቶች

ከ ClinicalTrials.gov የተገኘ መረጃ፣ በ5 ኦክቶ 2026 የተሰብሰቡ። እያንዳንዱ ጥናት የራሱን ቅድመ ሁኔታ ይወስናል፤ የጥናት ቡድኑ ማን መሳተፍ እንደሚችል ይወስናል።